Matches in Wikidata for { <http://www.wikidata.org/entity/Q59328265> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q59328265 description "im November 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q59328265 description "wetenschappelijk artikel" @default.
- Q59328265 description "наукова стаття, опублікована в листопаді 2018" @default.
- Q59328265 name "1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks" @default.
- Q59328265 name "1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks" @default.
- Q59328265 type Item @default.
- Q59328265 label "1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks" @default.
- Q59328265 label "1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks" @default.
- Q59328265 prefLabel "1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks" @default.
- Q59328265 prefLabel "1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks" @default.
- Q59328265 P1433 Q59328265-B9C46DBC-0009-40C7-BD76-2942D6695075 @default.
- Q59328265 P1476 Q59328265-1DCC94C0-69F4-4927-BB53-8E2EF94B7383 @default.
- Q59328265 P2093 Q59328265-07F5C207-D551-4DD7-B0C7-623D58982DE0 @default.
- Q59328265 P2093 Q59328265-36D1B0ED-B62D-4FE9-9C91-CFB558AA65C7 @default.
- Q59328265 P2093 Q59328265-72F0F867-6C45-415C-981B-5B04E5981875 @default.
- Q59328265 P2093 Q59328265-84BAA14E-5E2F-461C-A445-49482CA1F5D0 @default.
- Q59328265 P2093 Q59328265-BB7D112A-A4B1-4B5F-B580-F5E1D40D2F33 @default.
- Q59328265 P2093 Q59328265-CF1E5ADB-1A9E-4FCF-BABF-0D0A56B9D9F7 @default.
- Q59328265 P2093 Q59328265-D8C3E340-ED0C-4068-9544-00A6A1FA2B28 @default.
- Q59328265 P2093 Q59328265-F5F9BF83-A2BD-47C7-B782-9B5B8AA0D7FB @default.
- Q59328265 P2093 Q59328265-FE1BE53E-F99F-4BFB-9556-C462DF05BB79 @default.
- Q59328265 P275 Q59328265-f442e385-5708-4f8b-94f2-f77e22f84a71 @default.
- Q59328265 P304 Q59328265-2E64DAB6-0ECE-4E40-86E8-D172156A016C @default.
- Q59328265 P31 Q59328265-8070BEF1-E2C7-4121-871A-383423A64C13 @default.
- Q59328265 P356 Q59328265-BE244912-2E08-484E-BD98-A7416888FC45 @default.
- Q59328265 P433 Q59328265-1E923F7F-15DD-41B7-8FBD-F38F18AB23D5 @default.
- Q59328265 P478 Q59328265-474062EF-6BB2-441C-B10B-EE3F237F262F @default.
- Q59328265 P50 Q59328265-641D03AE-CD9B-40F6-A80A-381AEE0E5339 @default.
- Q59328265 P577 Q59328265-D9E46708-FA24-46CA-8157-8E7F47CCD99C @default.
- Q59328265 P6216 Q59328265-00cce5b4-549d-43f8-a64f-07149c3f51be @default.
- Q59328265 P932 Q59328265-18C79757-9234-4A31-BA1F-17CF81A17B25 @default.
- Q59328265 P356 OFY210.1635 @default.
- Q59328265 P1433 Q27725953 @default.
- Q59328265 P1476 "1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks" @default.
- Q59328265 P2093 "Christoph Sarrazin" @default.
- Q59328265 P2093 "David Victor" @default.
- Q59328265 P2093 "Douglas Dylla" @default.
- Q59328265 P2093 "Federico Mensa" @default.
- Q59328265 P2093 "Jordan J Feld" @default.
- Q59328265 P2093 "Sanjeev Arora" @default.
- Q59328265 P2093 "Stanley Wang" @default.
- Q59328265 P2093 "Tram Tran" @default.
- Q59328265 P2093 "Yiran B Hu" @default.
- Q59328265 P275 Q24082749 @default.
- Q59328265 P304 "S574-S575" @default.
- Q59328265 P31 Q13442814 @default.
- Q59328265 P356 "10.1093/OFID/OFY210.1635" @default.
- Q59328265 P433 "suppl_1" @default.
- Q59328265 P478 "5" @default.
- Q59328265 P50 Q91338492 @default.
- Q59328265 P577 "2018-11-01T00:00:00Z" @default.
- Q59328265 P6216 Q50423863 @default.
- Q59328265 P932 "6253425" @default.